KERX Keryx Biopharmaceuticals Inc.

KERYX 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit against Keryx Biopharmaceuticals Inc. - KERX

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until October 3, 2016 to file lead plaintiff applications in a securities class action lawsuit against Keryx Biopharmaceuticals Inc. (NasdaqCM: KERX). Investor losses must relate to purchases of the Company’s common stock between February 25, 2016, and August 1, 2016. This action is pending in the United States District Court for the Southern District of New York.

What You May Do

If you purchased shares of Keryx and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by October 3, 2016.

About Kahn Swick & Foti, LLC

KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

EN
01/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Keryx Biopharmaceuticals Inc.

 PRESS RELEASE

Keryx Biopharmaceuticals Stockholders Approve Merger with Akebia Thera...

Keryx Biopharmaceuticals Stockholders Approve Merger with Akebia Therapeutics BOSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that Keryx stockholders voted in favor of adopting the merger agreement among Keryx and inter alia Akebia Therapeutics, Inc. Separately today, Akebia announced that its stockholders voted to approve the share issuance proposal relating to the merger with Keryx at a special meeting of Akebia stockholders. “The...

 PRESS RELEASE

Glass Lewis Recommends that Keryx Biopharmaceuticals Stockholders Vote...

Glass Lewis Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics BOSTON, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that leading independent proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) recommends Keryx stockholders vote “FOR” the proposals relating to the proposed merger with Akebia Therapeutics, Inc. (Nasdaq: AKBA) at the Special Meeting of Keryx stockholders to be held...

 PRESS RELEASE

ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR...

ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics Leading proxy advisory firm recognizes the strategic and financial merits of the merger BOSTON, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) recommends Keryx stockholders vote “FOR” the merger and the proposals relating to the propos...

 PRESS RELEASE

Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Result...

Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Results Third quarter 2018 total revenues of $28.0 million including net U.S. Auryxia® (ferric citrate) product sales of $26.6 million, a 96 percent increase compared to the third quarter of 2017Approximately 47,500 Auryxia Prescriptions were written in the third quarter of 2018, nearly double the number reported in the third quarter of 2017Merger with Akebia Therapeutics on track to close by year end, subject to stockholder approval and the satisfaction of other closing conditions BOSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- K...

 PRESS RELEASE

Keryx Biopharmaceuticals to Release Third Quarter 2018 Financial Resul...

Keryx Biopharmaceuticals to Release Third Quarter 2018 Financial Results on Thursday, November 8, 2018 BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will release its third quarter 2018 financial results on Thursday, November 8, 2018 at approximately 4:30 p.m. ET. Keryx will not be conducting a conference call in conjunction with its third quarter 2018 earnings release given its pending merger with Akebia Therapeutics, Inc. ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch